


Hepatitis C: State of Medicaid Access Report Card

Colorado



| Grade | Recommendations to Improve Patient Access |
|-----------|---|
| A+ | <ul style="list-style-type: none"> Continue to ensure broad access to HCV treatment. |

State Overview

As of September 2022, 1,660,825 individuals were enrolled in Medicaid and CHIP.¹ It is estimated that as of 2016, 36,300 people were living with HCV in Colorado.² The state operates a Primary Care Case Management (PCCM) program known as the Accountable Care Collaborative.³ The PCCM program, which covers the majority of beneficiaries, is divided into seven geographic Regional Care Collaborative Organizations (RCCO).⁴ Additionally, Elevate Medicaid Choice (Denver Health Medical Plan) covers Medicaid-eligible individuals who live in a limited geographic area including Adams, Arapahoe, Denver, and Jefferson Counties.⁵ All RCCOs appear to follow the HCV treatment criteria set forth by the Colorado Department of Health Care Policy & Financing (DHCPF).⁶

The Colorado Medicaid Preferred Drug List includes Epclusa, Harvoni, ledipasvir/sofosbuvir, Mavyret, sofosbuvir/velpatasvir, and Vosevi.⁷

| Deductions | | Policy |
|----------------------------|-----------|--|
| Prior Authorization | | Prior authorization is not required for preferred HCV treatment regimens prescribed for initial treatment. Prescriptions may be written and filled for up to a 90-day supply. ⁸ |
| Fibrosis Restrictions | | Colorado Medicaid does not impose fibrosis restrictions. ⁹ |
| Substance Use Restrictions | | Colorado Medicaid does not impose substance use restrictions. ¹⁰ |
| Prescriber Restrictions | | Colorado Medicaid does not impose prescriber restrictions. ¹¹ |
| Retreatment Restrictions | | Colorado Medicaid does not impose undue retreatment restrictions. Prior authorization is required for retreatment using the standard prior authorization form. ¹² |
| Access in Managed Care | | All RCCOs appear to follow the criteria established by DHCPF. ¹³ |
| Additional Restrictions | | Colorado Medicaid does not impose additional restrictions. ¹⁴ |
| Total Deductions | -0 | Total Score [100-Deductions] |
| | | 100 |
| | | Grade |
| | | A+ |

Contact Your State Officials

Medicaid Office¹⁵: Adela Flores-Brennan, Director
1570 Grant Street, Denver, CO 80203-1818; Telephone: (303) 866-5929; Email Address: adela.flores-brennan@state.co.us

Pharmacy & Therapeutics Committee¹⁶: Brittany Schock, PharmD, Program Administrator
1570 Grant Street, Denver, CO 80203; Telephone: (303) 866-6371; Email Address: Brittany.Schock@state.co.us

Key Sources

Preferred Drug List: [Colorado Department of Health Care Policy and Financing, Preferred Drug List \(Jan. 2023\).](#)
Prior Authorization Form: [Colorado Department of Health Care Policy and Financing, Standard Prior Authorization \(PA\) Request Form \(Sept. 2019\).](#)
Clinical Criteria: Clinical criteria for HCV treatment are described in the Preferred Drug List, above.

-
- ¹ Centers for Medicare & Medicaid Services, Medicaid & CHIP in Colorado, <https://perma.cc/93JU-9KTN>.
 - ² HepVu, Local Data: Colorado (Jan. 2022), <https://perma.cc/R95D-55QR>.
 - ³ Health First Colorado, Regional Organizations, <https://perma.cc/HG8U-P772>.
 - ⁴ Colorado Department of Health Care Policy & Financing, Accountable Care Collaborative, <https://perma.cc/3U83-9UZG>.
 - ⁵ Denver Health Medical Plan, Denver Health Medicaid Choice, <https://perma.cc/G59R-462S>.
 - ⁶ Colorado Department of Health Care Policy & Financing, Health First Colorado Managed Care Contracts, <https://perma.cc/BBU4-J2BS>.
 - ⁷ Preferred Drug List.
 - ⁸ Preferred Drug List.
 - ⁹ Clinical Criteria.
 - ¹⁰ Clinical Criteria.
 - ¹¹ Clinical Criteria.
 - ¹² Clinical Criteria.
 - ¹³ Colorado Department of Health Care Policy & Financing, Health First Colorado Managed Care Contracts, <https://perma.cc/8T4W-AECZ>.
 - ¹⁴ Clinical Criteria.
 - ¹⁵ Colorado Department of Health Care Policy & Financing, Executive Leadership Team, <https://perma.cc/MR32-5T2P>.
 - ¹⁶ Colorado Department of Health Care Policy & Financing, Pharmacy and Therapeutics (P&T) Committee, <https://perma.cc/7AFG-WZR6>.